Barricaid and the topic of annular closure for herniated disc patients feature in two articles in the most recent issue by IJSS, the International Journal of Spine Surgery. This journal is the official publication of ISASS, the International Society for the Advancement of Spine Surgery. ISASS is among the largest societies of spine surgeons, and […]
Read moreIn the News
“Annular repair and the field of disc biology” named critical area for advancement, Becker’s Spine
This week, in a conversation with Becker’s Healthcare, Dr. Andrew Hecht (MD, Mt. Sinai Hospital, New York City) named “annular repair and the field of disc biology” one of the next big trends in spine. Barricaid is designed to close large annular holes, thereby reducing reherniation rates in patients at higher risk. Thank you, Dr. […]
Read more
Recap of a successful inaugural U.S. Disc Collective Meeting
Press ReleaseNew York NY, January 2020 – Intrinsic Therapeutics hosted its first U.S. Disc Collective Meeting on 16-17 January, 2020 in Manhattan, New York. 15 spine surgeons travelled to the East Coast in order to learn more about and exchange experiences on the topic of lumbar disc herniation. The program was themed around “A future of […]
Read moreBarricaid maker Intrinsic Therapeutics among top 20 private medtech companies
NewsThe Barricaid team is proud to be ranked among the top 20 private medtech companies to watch in 2020 by MDDI (Medical Device and Diagnostic Industry). To our mission, we stay committed to reducing needless suffering by ensuring Barricaid Annular Closure is accessible to patients and surgeons. Intrinsic Therapeutics’ Barricaid device is the only FDA […]
Read moreStudy in Spine: Annular Closure Device Good Option
NewsOn Tuesday, January 8th, 2019, Orthopedics This Week reports about a multicenter study from Northwestern University, The University of California-Davis, and the OLVG Hospital in Amsterdam, that has looked into costs associated with employing the Barricaid annular closure device for patients who are at high risk for recurrent herniation after a discectomy. Their work, “Cost-effectiveness of a bone-anchored annular […]
Read moreBarricaid superiority data presented at 25th Brussels international spine symposium
NewsThe Brussels International Spine Symposium (BISS) is globally recognized as one of the world leading, state-of-art annual meetings in Spine. Under the auspice of Drs. Marek Szpalski and Robert Gunzburg, the 25th anniversary meeting took place on 16-17 November 2018 reviewing the topic of Disc Herniation – Back to Basics: Controversies in diagnosis, management and costs. One […]
Read moreBest Paper Award SSA 2018 presented to Dr. Mark Arts
NewsDr. Mark Arts, a Dutch neurosurgeon from The Hague, delivered two podium presentations at the 2018 Spine Society of Australia 29th Annual Scientific Meeting, 27-29 April in Adelaide. One of his presented abstracts was elected as Best Paper of the 2018 Annual Scientific Meeting. Both talks were delivered in the Free Paper Session that focused on […]
Read moreIntrinsic Therapeutics announces the completion of a $49m financing
Press ReleaseFUNDING SUPPORTS FDA APPROVAL PROCESS AND GLOBAL MARKET ACCESS Boston, MA- May 10, 2017 -8:00am EST – Intrinsic Therapeutics, Inc. a medical device company that has developed a product to improve outcomes in lumbar discectomy patients, announced today that it recently closed a $49 million round of financing. The financing included a $28 million equity round […]
Read moreIntrinsic Therapeutics announces the filing of PMA application for its Barricaid Annular Closure device for lumbar discectomy patients
Press ReleaseBOSTON, Dec. 21, 2016 Intrinsic Therapeutics, Inc. announced today that the filing of its Pre-Market Approval (PMA) application with the Food & Drug Administration (FDA) for the Barricaid® Annular Closure device is complete. Barricaid has been shown to improve the outcomes of patients undergoing discectomy for herniated lumbar discs to relieve sciatica pain. “Approximately 1 million […]
Read moreIntrinsic Therapeutics announces the enrollment of the 400th patient in landmark Barricaid randomized trial
Press ReleaseIntrinsic Therapeutics today announced the enrollment of the 400th patient in a level 1, prospective, randomized, multi-center clinical trial evaluating the effectiveness of its Barricaid Prosthesis in improving outcomes for lumbar discectomy patients suffering from sciatica. The surgery was performed by Dr. Frederic Martens in Aalst, Belgium. The study is being conducted in Germany, Switzerland, Austria, and The Benelux with the goal […]
Read more